Profound Medical Corp. (PROF)
About Profound Medical Corp.
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-use devices and related services used in patient treatments.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $16.1M
- Net income
- -$42.6M
- Total assets
- $77.5M
- Market cap
- $242.0M
- Gross margin
- 70.8%
- Operating margin
- -256.3%
- Net margin
- -264.4%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $16.1M
- Cost of revenue
- $4.7M
- Gross profit
- $11.4M
- Operating expenses
- $52.6M
- Operating income
- -$41.3M
- Income tax
- $252.0K
- Net income
- -$42.6M
- EPS (basic)
- $1.41
- EPS (diluted)
- $1.41
Balance sheet
- Total assets
- $77.5M
- Current assets
- $76.1M
- Total liabilities
- $11.0M
- Current liabilities
- $6.1M
- Shareholders’ equity
- $66.4M
Cash flow
- Operating cash flow
- -$38.2M
- Investing cash flow
- -$242.0K
- Financing cash flow
- $41.1M
- Net cash flow
- $2.7M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $242.0M
- P/E ratio
- 5.1
- EPS (diluted)
- $1.41
- Shares outstanding
- 33.3M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- May 9, 2016
Profound Medical Corp. (PROF) Stock Price
- Reported a net loss of $42.6M in FY2025.
- Revenue grew 51% from FY2024 to FY2025.
- Gross margin of 70.8%, net margin -264.4%.
- Trading 16% below its 52-week high.
- Valued at a price-to-earnings (P/E) ratio of 5.1.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Profound Medical Corp..
Write a review
News about Profound Medical Corp.
News & sentiment via Polygon.io
Profound Medical Corp.: frequently asked questions
Is Profound Medical Corp. an American company?
Profound Medical Corp. is a US-based company, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Is Profound Medical Corp. publicly traded?
Yes — Profound Medical Corp. is a publicly traded company. Its stock trades under the ticker symbol PROF on the NASDAQ.
What does Profound Medical Corp. do?
Profound Medical Corp. is an American Medical Devices company in the Health & Beauty sector.
